Back

Targeting a shared neoepitope derived from non-canonical translation of c-MYC oncogene in cancer cells

Depil, S.; Baulu, E.; Bolon, A.; Etchegaray, E.; Raimundo, F.; Merienne, A.; Martin, J.; Grandsire, J.; Richard, T.; Tonon, L.; Dubois, C.; Estornes, Y.; Boulos, R.; Tabone, O.; Bonaventura, P.; Page, A.; Gardet, C.; Alcazer, V.; Hughes, S.; Gillet, B.; Gervois, N.; Labarriere, N.; Wang, Q.; Valladeau-Guilemond, J.; Chuvin, N.; Marcel, V.; Diaz, J.-J.

2024-05-27 immunology
10.1101/2024.05.23.595486 bioRxiv
Show abstract

Cancer cells rely on alternative modes of translation for protein synthesis, promoting internal ribosome entry site (IRES)-dependent translation of mRNA encoding pro-oncogenic factors. Furthermore, ribosomes translate mRNA with lower fidelity in tumor cells. We proposed that these translational modifications in cancer produce shared tumor-specific epitopes derived from IRES-containing oncogenes. To identify such neoepitopes, we developed an in silico-based method that we applied to c-MYC. We showed that the non-canonical translation of c-MYC mRNA in cancer cells, involving a (+1) ribosomal frameshift, generates a shared neoepitope which induces high-avidity T cells able to kill tumor cells in vitro and in vivo while sparing normal cells. Our data provide preclinical rationale for developing immunotherapies targeting this c-MYC-derived neoepitope and validate a new type of shared translation-associated neoantigens.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.